Introduction
Executive Summary
Onychomycosis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
MOB?015: Moberg Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
BB2603: Blueberry Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Early Stage Products (Phase I)
• Comparative Analysis
KP-607: Kaken Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
GX-03: Turn Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Onychomycosis Key Companies
Onychomycosis Key Products
Onychomycosis- Unmet Needs
Onychomycosis- Market Drivers and Barriers
Onychomycosis- Future Perspectives and Conclusion
Onychomycosis Analyst Views
Onychomycosis Key Companies
Appendix

List of Tables
Table 1 Total Products for Onychomycosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Onychomycosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Moberg Pharma
• Blueberry Therapeutics
• DermBiont
• Sanotize Research and Development
• Meiji Seika Pharma
• NovaBiotics
• Polichem
• Hallux
• Hexima
• Turn Therapeutics
• 9305-9954 Quebec
• Mycovia Pharmaceuticals
• CSA BioTech
• Kaken Pharmaceutical
• Turn Therapeutics